Johan Sein

589 citations

17 papers · 490 indexed · h-index 11

Impact in

Immunology top 10%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
Oncology top 10%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers

Papers in ⓘ

Oncology 14
- CAR-T cell therapy research 7
- Cancer Immunotherapy and Biomarkers 6
Immunology 10
- Immunotherapy and Immune Responses 8
- T-cell and B-cell Immunology 3
- Immune Cell Function and Interaction 3

Co-authors: Annemarie Hekman (7 shared papers)Florry A. Vyth‐Dreese (9 shared papers)Elaine M. Rankin (5 shared papers)W J Nooijen (5 shared papers)Michael Kersten (3 shared papers)Willem J. Nooijen (3 shared papers)Sjoerd Rodenhuis (2 shared papers)M.P.W. Gallee (3 shared papers)
Journals: Cancer Immunology Immunotherapy (4 papers)British Journal of Cancer (2 papers)Journal of Clinical Oncology (2 papers)Journal of Immunotherapy (2 papers)Clinical Cancer Research (1 paper)
Partner nations: Netherlands Slovakia United States

In The Last Decade

Johan Sein

17 papers receiving 471 citations

Peers

Countries citing papers authored by Johan Sein

Since Specialization

Citations

This map shows the geographic impact of Johan Sein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johan Sein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johan Sein more than expected).

Fields of papers citing papers by Johan Sein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Johan Sein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johan Sein. The network helps show where Johan Sein may publish in the future.

Co-authors

The 25 scholars most cited alongside Johan Sein, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Johan Sein Line = papers co-authored together Johan Sein links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work
1	Immunogenicity, Including Vitiligo, and Feasibility of Vaccination With AutologousGM-CSF–Transduced Tumor Cells in Metastatic Melanoma Patients Journal of Clinical Oncology ·Rosalie M. Luiten, Esther W. M. Kueter, Wolter J. Mooi, M.P.W. Gallee, Elaine M. Rankin, Winald R. Gerritsen, S Clift, Willem J. Nooijen, P. Weder, Willeke F. van de Kasteele, Johan Sein, Paul C.M. van den Berk, Omgo E. Nieweg, Anton Berns, Hergen Spits, Gijsbert C. de Gast	2005	90
2	Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody Cancer Immunology Immunotherapy ·Annemarie Hekman, A. Honselaar, Wim M.J. Vuist, Johan Sein, Sjoerd Rodenhuis, W.W. ten Bokkel Huinink, R. Somers, P Rümke, C J Melief	1991	78
3	Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. PubMed ·G C de Gast, Heinz‐Josef Klümpen, Florry A. Vyth‐Dreese, Michael Kersten, Natascha Verra, Johan Sein, D. Batchelor, W J Nooijen, Jan H. Schornagel	2000	48
4	Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2. PubMed ·Erik Hooijberg, Johan Sein, P C van den Berk, A. A. M. Hart, Martin A. van der Valk, W. Martin Kast, Cornelis J.M. Melief, Annemarie Hekman	1995	47
5	On the Role of Melanoma-Specific CD8+ T-Cell Immunity in Disease Progression of Advanced-Stage Melanoma Patients Clinical Cancer Research ·Monique van Oijen, Adriaan D. Bins, Sjoerd G. Elias, Johan Sein, P. Weder, Gijsbert de Gast, Henk Mallo, M.P.W. Gallee, Harm van Tinteren, Ton N. Schumacher, John B.A.G. Haanen	2004	41
6	Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFNα in patients with metastatic melanoma British Journal of Cancer ·G. C. de Gast, D. Batchelor, Michael Kersten, Florry A. Vyth‐Dreese, Johan Sein, Willeke F. van de Kasteele, W J Nooijen, Omgo E. Nieweg, M A de Waal, Willem Boogerd	2003	36
7	Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma British Journal of Cancer ·Natascha Verra, Slinger Jansen, Gerard Groenewegen, Henk Mallo, Michael Kersten, Axel Bex, Florry A. Vyth‐Dreese, Johan Sein, Willeke van de Kasteele, W J Nooijen, Mirjam de Waal, Simon Horenblas, G C de Gast	2003	30
8	Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19 Cancer Immunology Immunotherapy ·L. Tom Vlasveld, Annemarie Hekman, Florry A. Vyth‐Dreese, Cornelis J. M. Melief, Johan Sein, Arie C. Voordouw, Trees A. M. Dellemijn, Elaine M. Rankin	1995	27
9	Infiltration of Activated Dendritic Cells and T Cells in Renal Cell Carcinoma Following Combined Cytokine Immunotherapy European Urology ·Natascha Verra, Daphne de Jong, Axel Bex, Diane Batchelor, Trees A. M. Dellemijn, Johan Sein, Willem J. Nooijen, W. Meinhardt, Simon Horenblas, Gijsbert de Gast, Florry A. Vyth‐Dreese	2005	25
10	Phase I Clinical Study With Multiple Peptide Vaccines in Combination With Tetanus Toxoid and GM-CSF in Advanced-stage HLA-A0201-positive Melanoma Patients Journal of Immunotherapy* ·Adriaan D. Bins, Henk Mallo, Johan Sein, Colette van den Bogaard, Willem J. Nooijen, Florry A. Vyth‐Dreese, Bastiaan Nuijen, Gijsbert C. de Gast, John B.A.G. Haanen	2007	19
11	Reconstitution of recombinant interleukin-2 (rIL-2): a comparative study of various rIL-2 muteins European Journal of Cancer ·Lodewijk Th. Vlasveld, Jos H. Beijnen, Johan Sein, Elaine M. Rankin, Cornelis J.M. Melief, Annemarie Hekman	1993	11
12	Characterization of a Series of Isotype Switch Variants of a New CD20 Monoclonal Antibody Hybridoma ·Erik Hooijberg, Johan Sein, P C van den Berk, Annemarie Hekman	1996	10
13	Reinfusion of Autologous Lymphocytes With Granulocyte-Macrophage Colony-Stimulating Factor Induces Rapid Recovery of CD4+ and CD8+ T Cells After High-Dose Chemotherapy for Metastatic Breast Cancer Journal of Clinical Oncology ·G. C. de Gast, Florry A. Vyth‐Dreese, W J Nooijen, C. J.C. van den Bogaard, Johan Sein, MJ Holtkamp, G. A.M. Linthorst, Joke W. Baars, Jan H. Schornagel, Sjoerd Rodenhuis	2002	10
14	Treatment of low-grade non-Hodgkin?s lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19 Cancer Immunology Immunotherapy ·L. T. Vlasveld, Annemarie Hekman, Florry A. Vyth‐Dreese, Cornelis J.M. Melief, Johan Sein, Arie C. Voordouw, Trees A. M. Dellemijn, Elaine M. Rankin	1995	7
15	Lysis of Syngeneic Tumor B Cells by Autoreactive Cytotoxic T Lymphocytes Specific for a CD 19 Antigen-Derived Synthetic Peptide Journal of Immunotherapy ·Erik Hooijberg, Marjan J.W. Visseren, Paul C.M. van den Berk, P Jellema, Petra Romeijn, Johan Sein, Ellen I.H. van der Voort, Annemarie Hekman, Ferry Ossendorp, Cornelis J.M. Melief	1996	5
16	Possible role for cytotoxic lymphocytes in the pathogenesis of acute interstitial nephritis after recombinant interleukin-2 treatment for renal cell cancer Cancer Immunology Immunotherapy ·Lodewijk Th. Vlasveld, E. van de Wiel-van Kemenade, Annemiek J. de Boer, Johan Sein, M.P.W. Gallee, Raymond T. Krediet, C. J. M. Mellief, Elaine M. Rankin, Annemarie Hekman, Carl G. Figdor	1993	4
17	Lack of anti-tumour reactivity despite enhanced numbers of circulating natural killer T cells in two patients with metastatic renal cell carcinoma Clinical & Experimental Immunology ·Florry A. Vyth‐Dreese, Johan Sein, Willeke van de Kasteele, T. Dellemijn, Colette van den Bogaard, W J Nooijen, G. C. de Gast, J.B.A.G. Haanen, Axel Bex	2010	2

About Johan Sein

Johan Sein is a scholar working on Oncology, Immunology, Radiology, Nuclear Medicine and Imaging, Molecular Biology and Pathology and Forensic Medicine, having authored 17 papers that have together received 490 indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (8 papers), CAR-T cell therapy research (7 papers), Cancer Immunotherapy and Biomarkers (6 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Lymphoma Diagnosis and Treatment (3 papers), T-cell and B-cell Immunology (3 papers), Immune Cell Function and Interaction (3 papers) and vaccines and immunoinformatics approaches (2 papers). The work is most often cited by research in Immunology (316 citations), Oncology (278 citations), Radiology, Nuclear Medicine and Imaging (147 citations), Pathology and Forensic Medicine (56 citations) and Genetics (30 citations). Johan Sein has collaborated with scholars based in Netherlands, Slovakia and United States. Frequent co-authors include Annemarie Hekman, Florry A. Vyth‐Dreese, Elaine M. Rankin, W J Nooijen, Michael Kersten, Willem J. Nooijen, Sjoerd Rodenhuis, M.P.W. Gallee, W.W. ten Bokkel Huinink and P Rümke. Their work appears in journals such as Cancer Immunology Immunotherapy, British Journal of Cancer, Journal of Clinical Oncology, Journal of Immunotherapy and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact